LON:MTPH Biodexa Pharmaceuticals (MTPH) Share Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free MTPH Stock Alerts GBX 18 -1.00 (-5.26%) (As of 03/27/2023) Add Compare Share Share Today's Range 12.50▼ 2050-Day Range 18▼ 1852-Week Range 0.90▼ 20Volume73,672 shsAverage Volume617,252 shsMarket Capitalization£31.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biodexa Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Biodexa Pharmaceuticals Stock (LON:MTPH)Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More MTPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTPH Stock News HeadlinesApril 16, 2024 | americanbankingnews.comBiodexa Pharmaceuticals (LON:MTPH) Stock Crosses Below Fifty Day Moving Average of $18.00March 28, 2024 | seekingalpha.comSLRX Salarius Pharmaceuticals, Inc.April 19, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 23, 2024 | msn.comBiodexa stock slides 7% amid data for two drug studiesFebruary 8, 2024 | markets.businessinsider.comBiodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsFebruary 7, 2024 | msn.comBiodexa stock jumps on allowance of U.S. patent covering TolimidoneFebruary 7, 2024 | tmcnet.comBiodexa Announces Allowance of U.S. Patent Covering TolimidoneDecember 19, 2023 | msn.comBiodexa Pharmaceuticals down 21%, prices equity offeringApril 19, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...November 28, 2023 | msn.comWhat's Going On With Biodexa Pharmaceuticals Stock (BDRX) Today?November 27, 2023 | marketwatch.comBiodexa Enters Worldwide Licensing Deal for TolimidoneNovember 27, 2023 | msn.comBiodexa jumps on licensing deal for diabetes candidateNovember 27, 2023 | marketwatch.comBiodexa Pharma Shares Double After Licensing Deal for TolimidoneNovember 19, 2023 | morningstar.comBiodexa Pharmaceuticals Plc ADR BDRXOctober 3, 2023 | tmcnet.comBiodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaJune 23, 2023 | msn.comBiodexa Pharmaceuticals announces ADR ratio changeMay 18, 2023 | technews.tmcnet.comBiodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian BiopharmaceuticalsApril 22, 2023 | investing.comBiodexa Pharmaceuticals PLC DRC (BDRX)April 3, 2023 | finance.yahoo.comBiodexa Pharmaceuticals PLC Announces Issue of Pre-Funded WarrantsMarch 28, 2023 | finance.yahoo.comBiodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of EquityMarch 27, 2023 | finance.yahoo.comMidatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal DiseaseMarch 24, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Results of General MeetingMarch 10, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Further re: Notice of General MeetingFebruary 15, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker ChangeFebruary 9, 2023 | marketwatch.comMidatech Pharma to Raise About $6 Million to Develop Cancer TreatmentJanuary 6, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Posting of Circular and Notice of General MeetingDecember 19, 2022 | finance.yahoo.comBioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plcSee More Headlines Receive MTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/10/2020Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MTPH CUSIPN/A CIKN/A Webwww.midatechpharma.com Phone+44-1235-841575FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.47% Return on Assets-52.50% Debt Debt-to-Equity Ratio9.52 Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales£645,000.00 Price / Sales48.38 Cash FlowGBX 20.53 per share Price / Cash Flow0.88 Book ValueGBX 152 per share Price / Book0.12Miscellaneous Outstanding Shares173,350,000Free FloatN/AMarket Cap£31.20 million OptionableNot Optionable Beta1.22 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Stephen A. Stamp (Age 61)CEO, CFO, Company Sec. & Director Comp: $233.87kDr. Dmitry Zamoryakhin M.D. (Age 43)Chief Scientific Officer Comp: $231.47kDr. Daniel Palmer MBAPh.D., VP of TechnologyDr. Tim Sparey Ph.D.Chief Bus. OfficerMr. Justin Barry BSc (Hons.)MBIOL, CBIOL, QP, Head of ManufacturingMr. Vincent HolmesVP & Head of Clinical OperationsMr. David Benharris (Age 58)Pres of Midatech Pharma US Inc Ms. Fiona SharpGroup Financial ControllerMore ExecutivesKey CompetitorsCollagen Solutions plc (COS.L)LON:COS4D pharmaLON:DDDDC4X DiscoveryLON:C4XDOKYO PharmaLON:OKYOArecor TherapeuticsLON:ARECView All Competitors MTPH Stock Analysis - Frequently Asked Questions How have MTPH shares performed in 2024? Biodexa Pharmaceuticals' stock was trading at GBX 18 at the beginning of 2024. Since then, MTPH shares have increased by 0.0% and is now trading at GBX 18. View the best growth stocks for 2024 here. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals Plc (LON:MTPH) released its quarterly earnings results on Thursday, September, 10th. The company reported ($64.00) earnings per share for the quarter. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include Aldeyra Therapeutics (ALDX), Barclays (BARC), Telefonaktiebolaget LM Ericsson (publ) (ERIC), Futura Medical (FUM), Lloyds Banking Group (LLOY), Biodexa Pharmaceuticals (MTP), Intec Pharma (NTEC), Pearson (PSON), Royal Mail (RMG) and AON (AON). How do I buy shares of Biodexa Pharmaceuticals? Shares of MTPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MTPH) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.